• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4598322)   Today's Articles (654)   Subscriber (49356)
Number Citation Analysis
101
Takahara N, Isayama H, Nakai Y, Ioka T, Kanai M, Sasaki T, Furuse J, Koike K. A single arm, prospective multicenter phase II study FOLFIRINOX in patients with advanced and recurrent biliary tract cancer. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.4_suppl.tps514] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
102
Ioka T, Katayama K, Takada R, Ohkawa K, Takahashi H, Teshima T. The phase I study of concurrent chemoradiotherapy using a combination of gemcitabine and nab-paclitaxel for unresectable locally advanced pancreatic cancer: Update. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.4_suppl.462] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
103
Matsubara T, Nishida T, Tomimaru Y, Yamamoto M, Hayashi S, Nakajima S, Fukui K, Dono K, Adachi S, Ioka T, Kanai M, Inada M. Histological complete response in a patient with advanced biliary tract cancer treated by gemcitabine/cisplatin/S-1 combination chemotherapy: A case report. Mol Clin Oncol 2017;5:757-761. [PMID: 28101354 PMCID: PMC5228213 DOI: 10.3892/mco.2016.1065] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2016] [Accepted: 10/13/2016] [Indexed: 12/30/2022]  Open
104
Ioka T, Komatsu Y, Mizuno N, Tsuji A, Ohkawa S, Tanaka M, Iguchi H, Ishiguro A, Kitano M, Satoh T, Yamaguchi T, Takeda K, Kida M, Eguchi K, Ito T, Munakata M, Itoi T, Furuse J, Hamada C, Sakata Y. Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer. Br J Cancer 2017;116:464-471. [PMID: 28081543 PMCID: PMC5318973 DOI: 10.1038/bjc.2016.436] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Revised: 10/31/2016] [Accepted: 12/05/2016] [Indexed: 12/18/2022]  Open
105
Ioka T, Ueno M, Ueno H, Kabir S, Tokudome T, Ikeda M. 274TiP A randomized phase 2 study of nanoliposomal irinotecan (nal-IRI, BAX2398)-containing regimen in Japanese patients with metastatic pancreatic adenocarcinoma (mPAC). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw582.055] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]  Open
106
Ioka T, Katayama K, Ookawa K, Takahashi H, Teshima T. Gemcitabine plus nab-paclitaxel in Japan. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw470.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]  Open
107
Kanai M, Hatano E, Nagano H, Ioka T. Clinical trials of gemcitabine/cisplatin/S-1 (GCS) combination therapy for patients with advance biliary tract cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw486.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]  Open
108
Ioka T, Fukutomi A, Mizusawa J, Katayama H, Nakamura S, Ito Y, Hiraoka N, Ueno M, Ikeda M, Sugimori K, Shimizu K, Okusaka T, Ozaka M, Yanagimoto H, Nakamori S, Azuma T, Hosokawa A, Sata N, Mine T, Furuse J. Randomized phase II study of S-1 and concurrent radiotherapy with versus without induction chemotherapy of gemcitabine for locally advanced pancreatic cancer (LAPC): Final analysis of JCOG1106. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw371.13] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]  Open
109
Yoneyama T, Ohtsuki S, Honda K, Kobayashi M, Iwasaki M, Uchida Y, Okusaka T, Nakamori S, Shimahara M, Ueno T, Tsuchida A, Sata N, Ioka T, Yasunami Y, Kosuge T, Kaneda T, Kato T, Yagihara K, Fujita S, Huang W, Yamada T, Tachikawa M, Terasaki T. Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics. PLoS One 2016;11:e0161009. [PMID: 27579675 PMCID: PMC5007017 DOI: 10.1371/journal.pone.0161009] [Citation(s) in RCA: 68] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2016] [Accepted: 07/28/2016] [Indexed: 12/24/2022]  Open
110
Kataoka TR, Ioka T, Tsukamoto Y, Matsumura M, Ishiguro S, Nishizawa Y. Nuclear Expression of STAT5 in Intraductal Papillary Mucinous Neoplasms of the Pancreas. Int J Surg Pathol 2016;15:277-81. [PMID: 17652536 DOI: 10.1177/1066896907302233] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
111
Honda K, Kobayashi M, Okusaka T, Morizane C, Rinaudo JA, Huang Y, Marsh T, Shimahara M, Ueno T, Tsuchida A, Sata N, Ioka T, Kosuge T, Yasunami Y, Yoshida M, Azuma T, Srivastava S, Yamada T. Plasma biomarker for detection of early-stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies for apolipoprotein-A2 isoforms. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.4106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
112
Van Cutsem E, Lenz HJ, Furuse J, Tabernero J, Heinemann V, Ioka T, Bazin I, Ueno M, Csõszi T, Wasan H, Melichar B, Karasek P, Macarulla TM, Guillen C, Kalinka-Warzocha E, Horvath Z, Prenen H, Schlichting M, Ibrahim A, Bendell JC. MAESTRO: A randomized, double-blind phase III study of evofosfamide (Evo) in combination with gemcitabine (Gem) in previously untreated patients (pts) with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC). J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.4007] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
113
Ueno H, Ikeda M, Ueno M, Mizuno N, Ioka T, Omuro Y, Nakajima TE, Furuse J. Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 2016;77:595-603. [PMID: 26842789 DOI: 10.1007/s00280-016-2972-3] [Citation(s) in RCA: 104] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2015] [Accepted: 01/18/2016] [Indexed: 01/05/2023]
114
Van Cutsem E, Lenz HJ, Furuse J, Tabernero J, Heinemann V, Ioka T, Bazin I, Ueno M, Csõszi T, Wasan H, Melichar B, Karasek P, Macarulla T, Guillén Ponce C, Kalinka-Warzocha E, Horvath Z, Prenen H, Schlichting M, Mehdi F, Bendell JC. Evofosfamide (TH-302) in combination with gemcitabine in previously untreated patients with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma: Primary analysis of the randomized, double-blind phase III MAESTRO study. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.4_suppl.193] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]  Open
115
Yamashina T, Takada R, Uedo N, Akasaka T, Hanaoka N, Takeuchi Y, Higashino K, Ioka T, Ishihara R, Teshima T, Nishiyama K, Iishi H. Prospective small bowel mucosal assessment immediately after chemoradiotherapy of unresectable locally advanced pancreatic cancer using capsule endoscopy: a case series. Ann Gastroenterol 2016;29:386-8. [PMID: 27366048 PMCID: PMC4923833 DOI: 10.20524/aog.2016.0063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/13/2015] [Accepted: 01/15/2016] [Indexed: 11/25/2022]  Open
116
Ueno M, Okusaka T, Omuro Y, Isayama H, Fukutomi A, Ikeda M, Mizuno N, Fukuzawa K, Furukawa M, Iguchi H, Sugimori K, Furuse J, Shimada K, Ioka T, Nakamori S, Baba H, Komatsu Y, Takeuchi M, Hyodo I, Boku N. A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer. Ann Oncol 2015;27:502-8. [PMID: 26681680 PMCID: PMC4769993 DOI: 10.1093/annonc/mdv603] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2015] [Accepted: 12/01/2015] [Indexed: 12/27/2022]  Open
117
Fujiwara Y, Kobayashi S, Nagano H, Kanai M, Hatano E, Toyoda M, Ajiki T, Takashima Y, Yoshimura K, Hamada A, Minami H, Ioka T. Pharmacokinetic Study of Adjuvant Gemcitabine Therapy for Biliary Tract Cancer following Major Hepatectomy (KHBO1101). PLoS One 2015;10:e0143072. [PMID: 26633034 PMCID: PMC4669083 DOI: 10.1371/journal.pone.0143072] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2015] [Accepted: 10/29/2015] [Indexed: 12/19/2022]  Open
118
Ioka T, Katayama K, Ashida R, Takahashi H, Teshima T, Sakon M. [The progress of chemotherapy for advanced pancreatic cancer]. NIHON SHOKAKIBYO GAKKAI ZASSHI = THE JAPANESE JOURNAL OF GASTRO-ENTEROLOGY 2015;112:2119-2126. [PMID: 26638783 DOI: 10.11405/nisshoshi.112.2119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
119
Ioka T, Katayama K, Ashida R. S-1 based chemotherapy for metastatic pancreatic cancer. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv404.03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]  Open
120
Omuro Y, Ueno H, Ikeda M, Ueno M, Mizuno N, Ioka T, Nakajima T, Furuse J. Updated analysis of weekly nab-Paclitaxel (P)+ Gemcitabine (G) with metastatic pancreatic cancer (MPC): Phase I / II trial. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv471.40] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]  Open
121
Okusaka T, Ikeda M, Fukutomi A, Ioka T, Furuse J, Ohkawa S, Isayama H, Boku N. Response to Y. Sasaki et al.: Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer? Cancer Sci 2015;106:1101-2. [PMID: 26268894 PMCID: PMC4556402 DOI: 10.1111/cas.12709] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2015] [Accepted: 05/26/2015] [Indexed: 01/01/2023]  Open
122
Ioka T, Ikeda M, Fukutomi A, Morizane C, Kasuga A, Takada R, Takahashi H, Todaka A, Okusaka T, Creasy C, Gorman S, Felitsky D, Kawamura T, Kobayashi M, Furuse J. 2382 A proof-of-concept study of MEK inhibitor trametinib monotherapy in patients with biliary tract cancers. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31298-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
123
Honda K, Kobayashi M, Okusaka T, Nakamori S, Shimahara M, Ueno T, Tsuchida A, Sata N, Ioka T, Yasunami Y, Masaru Y, Kosuge T, Jung G, Yamada T. 409 Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies against apolipoprotein-AII isoforms. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30243-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
124
Ioka T, Kanai M, Kobayashi S, Sakai D, Kitasato A, Yamaue H, Hayashi H, Chayahara N, Takahashi M, Yamada T, Hatano E, Goto T, Fujimoto J, Murakami M, Kamei K, Yoshimura K. Randomised phase III study of gemcitabine, cisplatin plus S-1 (GCS) compared with gemcitabine plus cisplatin (GC) for unresectable or recurrent biliary tract cancer (KHBO1401-MITSUBA). J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.tps4141] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
125
Yanagimoto H, Okusaka T, Ishii H, Furuse J, Ohkawa S, Fukutomi A, Ioka T, Sho M, Nakamori S, Kitano M, Sugimori K, Maguchi H, Imaoka H, Baba H, Shimizu A, Yokota I, Ohashi Y, Yamaue H. Interim safety analysis of a randomized phase II trial comparing alternate-day oral therapy using S-1 with the standard regimen as a first-line treatment for patients with advanced pancreatic cancer. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.e15267] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
PrevPage 5 of 9 1245689Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA